FLUID & DRUG DELIVERY SYSTEM SALES TO TOP $7 BILLION BY 2000, LED BY NEW MODALITIES.MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--U.S. sales of fluid and drug delivery systems will grow from just under $5 billion in 1993 to just over $7 billion by the year 2000 at a 5 percent compound annual rate, projects a new study just released by Frost & Sullivan. By the year 2000, implantable pumps implantable pump Therapeutics A device installed under the skin to administer a steady dose of drugs will account for 51 percent of total market revenues, nasal delivery systems 15 percent, nebulizers 11 percent, infusion pumps infusion pump A device designed to deliver drugs and/or 'biologicals', at low doses and at a constant or controllable rate; ↑ rates of delivery in such devices may be associated with local hemolysis, compromising the potential benefits of a calibrated delivery 10 percent and administration sets 8 percent, forecasts the report, U.S. FLUID AND DRUG DELIVERY SYSTEM MARKETS: ANNUAL UPDATEIDENTIFIES MARKET HOT SPOTS hot spots acute moist dermatitis. . As healthcare facilities look to fluid and drug delivery systems to cut costs, manufacturers have responded by developing new systems and offering better pricing. Multi-channel large- volume pumps, modular multi-channel devices, and syringe syringe /sy·ringe/ (si-rinj´) (sir´inj) an instrument for injecting liquids into or withdrawing them from any vessel or cavity. and ambulatory infusion pumps have helped reduce healthcare costs. Some infusion pump and set manufacturers offer additional cost reductions to facilities buying solutions bundled with infusion systems. The newest systems -- variable-release, transdermal transdermal /trans·der·mal/ (-der´m'l) entering through the dermis, or skin, as in administration of a drug via ointment or patch. trans·der·mal adj. Through or by way of the skin. and intranasal in·tra·na·sal adj. Within the nose. -- have led growth and enhanced drug efficacy. The last five years have seen development of three new transdermal systems, six variable release medications and two new intranasal drugs. These newer delivery systems have strong future growth prospects. Many now-oral medications, for example, could be converted into variable-release preparations. More drugs and hormones could be delivered transdermally and more drugs could be administered nasally. Liposomes Liposomes Aqueous compartments enclosed by lipid bilayer membranes; liposomes are also known as lipid vesicles. Phospholipid molecules consist of an elongated nonpolar (hydrophobic) structure with a polar (hydrophilic) structure at one end. , not yet on the market, will increase efficacy and reduce side effects Side effects Effects of a proposed project on other parts of the firm. of antifungal antifungal /an·ti·fun·gal/ (-fung´gal) 1. destructive to fungi, or suppressing their reproduction or growth; effective against fungal infections. 2. an agent that so acts. and chemotherapeutic agents This is a list of specific pharmacologic agents that are known to be of use in the treatment of cancer, otherwise known as chemotherapeutic agents. This list is organized by "type" of agent, though the subsections are not necessarily definitive and are subject to revision. . Incorporating these drugs into liposomes will allow delivery of smaller doses to specifically targeted sites. The maintenance of steady therapeutic levels through variable- release eliminates the harmful side effects of high drug concentrations and the low efficacy of inadequate concentration levels. Transdermal delivery also maintains even medication levels by releasing small drug amounts through skin over extended periods of time. Nasal administration offers greater efficacy at lower doses, rapid absorption into the bloodstream through mucous membranes Mucous membranes The inner tissue that covers or lines body cavities or canals open to the outside, such as nose and mouth. These membranes secrete mucus and absorb water and salts. Mentioned in: Leprosy, Pulmonary Fibrosis, Topical Anesthesia , and increased convenience. The more conventional systems are generally mature businesses with slow if any growth although they include pockets of moderate to strong growth, such as ambulatory and syringe pumps. Key competitive factors in these markets will continue to be technology, products and marketing. Frost & Sullivan is an international high-technology research firm. All Frost & Sullivan reports are based on extensive interviews with marketing and technical experts from selected companies in each market segment. Primary research is validated by thorough analysis of available secondary research. Frost & Sullivan is the leading publisher worldwide of high-technology research reports. Report: 5087-54 Publication Date:1994 Price: $2295 Total Fluid and Drug Delivery System Market: Revenue Forecasts (U.S.), 1990-20003-1 Total Fluid and Drug Delivery System Market: Revenue Forecasts (U.S.), 1990-2000gures Revenue RevenuesGrowth Rate Year ($ Billion) (%) 1990 2.34 --- 1991 3.27 39.7 1992 4.74 45.1 1993 4.95 4.4 1994 5.42 9.5 1995 5.81 7.1 1996 6.14 5.6 1997 6.46 5.2 1998 6.74 4.4 1999 6.94 3.0 2000 7.09 2.2 Compound Annual Growth Rate (1993-2000): 5.3% Note: All figures are rounded. Source: Frost & Sullivan CONTACT: For further information please contact: Amy Arnell Kristina Menzefricke Nadge Keryhuel Mountain View London Paris (415) 961-9000 44 71 730 3438 33 1 4742 9127 (415) 961-5042(fax) 44 71 730 3343 33 1 4742 9129 REPEATS: New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of 212-575-8822 or 800-221-2462; Boston 617-330-5311 or |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion